-

Parse Biosciences to Participate in Canaccord Genuity Investor Conference

CEO and co-founder Alex Rosenberg, Ph.D. joining panel discussion at November 17 event in New York

--(BUSINESS WIRE)--Parse Biosciences

WHAT:

 

Senior executives from Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, will participate in the Canaccord Genuity Medtech, Diagnostics and Digital Health & Services Forum. The one-day event will profile public and private companies across the medical technology, diagnostic and digital health & services sectors.

 

 

 

 

 

 

WHO:

 

Parse Biosciences CEO and co-founder Alex Rosenberg, Ph.D. will participate on a panel titled, “Oh Me, Oh My, Multiomics: A Panel Discussion of Scientists and Executives Highlighting Spatial Biology, Single Cell Analysis, Proteomics and Morpholomics.”

 

 

 

 

 

Alex Rosenberg and Parse Biosciences CFO Britton Russell will be available for one-on-one meetings with institutional investors during the conference.

 

 

 

 

 

 

WHEN:

 

Panel: Thursday, November 17, 1:00 - 1:55 pm

 

 

 

 

 

 

WHERE:

 

Javits Center, New York City

​About Parse Biosciences

Parse Biosciences is a leading provider of accessible and scalable single cell sequencing solutions with the mission of accelerating progress in human health and scientific research. The company’s pioneering approach for single cell sequencing has already enabled groundbreaking discoveries which have led to new understandings of cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system. The company’s commercially available instrument-free products provide researchers with the ability to perform single cell sequencing at low cost with unprecedented scale and ease. Parse Biosciences is headquartered in Seattle.

To learn more about Parse Biosciences, please visit: https://www.parsebiosciences.com and follow us on Twitter and LinkedIn.

Contacts

Investors: Robert Uhl, ICR Westwicke: robert.uhl@westwicke.com | 619.228.5886
Media: Lisa Owen, Parse Biosciences: lisa@parsebiosciences.com | 206-851-6246

Parse Biosciences


Release Summary
Parse Biosciences will Participate in the Canaccord Genuity Investor Conference
Release Versions

Contacts

Investors: Robert Uhl, ICR Westwicke: robert.uhl@westwicke.com | 619.228.5886
Media: Lisa Owen, Parse Biosciences: lisa@parsebiosciences.com | 206-851-6246

More News From Parse Biosciences

Parse Biosciences and Nomic Announce 100 Million Cell, Multimodal AI-ready Dataset for Immune Biology

SEATTLE & MONTREAL--(BUSINESS WIRE)--Parse Biosciences and Nomic Bio partner on Cascade, a 100 million cell dataset pairing RNA and protein data to speed immune drug target discovery....

Parse Biosciences Launches Evercode MAX, Enabling Researchers to Profile More Cells and Samples with Greater Flexibility

SEATTLE--(BUSINESS WIRE)--Parse Biosciences, the leading provider of scalable and accessible single cell sequencing and a QIAGEN company, today announced that Evercode™ MAX, a modular configuration of its flagship Evercode single cell sequencing platform, is now shipping to customers. Using the same instrument-free workflow, researchers can profile up to 2.5 times as many cells across up to twice as many samples within their existing budget, or run the same experiment at roughly half the overal...

Xpress Genomics Joins Parse Biosciences’ Certified Service Provider Network

SEATTLE--(BUSINESS WIRE)--Xpress Genomics joins Parse Biosciences' CSP program as the first Nordic partner, offering Evercode single cell sequencing to Swedish researchers...
Back to Newsroom